July 1st 2020, 10:37pm
C. Ola Landgren, MD, PhD, discusses the efficacy of idecabtagene vicleucel in the treatment of patients with relapsed/refractory myeloma.
June 30th 2020, 6:30pm
Caitlin Costello, MD, discusses the role of daratumumab in multiple myeloma.
June 30th 2020, 3:02pm
Shaji K. Kumar, MD, discusses stem cell mobilization multiple myeloma.
June 30th 2020, 2:30pm
Katja Weisel, MD, discusses the safety profile of isatuximab-irfc in combination with carfilzomib, lenalidomide, and dexamethasone in high-risk patients with newly diagnosed multiple myeloma.
June 30th 2020, 2:00pm
C. Ola Landgren, MD, PhD, discusses investigational cellular therapies in multiple myeloma.
June 29th 2020, 7:45pm
Luciano J. Costa, MD, PhD, sheds light on CC-93269, a BCMA 2+1 T-cell engager, under examination in a phase 1 dose-finding study in relapsed/refractory multiple myeloma.
June 29th 2020, 2:04pm
Sagar Lonial, MD, FACP, discusses the updated data from DREAMM-2 with belantamab mafodotin, associated toxicities to be aware of, and future directions for research.
June 29th 2020, 1:25pm
Noopur Raje, MD, discusses the rationale for CAR T-cell therapy in multiple myeloma.
June 29th 2020, 1:13pm
María-Victoria Mateos, MD, PhD, discusses the significance of the ongoing phase 3 CANOVA trial, which is examining venetoclax in patients with relapsed/refractory t(11;14) multiple myeloma.
June 26th 2020, 8:30pm
Caitlin Costello, MD, discusses proper dosing of carfilzomib in relapsed/refractory multiple myeloma.
